Samples with poor response (<90% necrosis of tumor cells) to neoadjuvant chemotherapy showed reduced SMARCB1 gene expression compared with samples with good chemotherapeutic response (≥ 90% necrosis of tumor cells; 133.0 ± 66.7 versus 146.7 ± 58.4, P=0.49) (Figure 5B). This evidence concerns the gene SMARCB1 and neoplasm.